// App-Quantinova.ai

e12544 : Broad, hybrid capture-based next generation sequencing identified actionable genomic alterations in HER2-negative breast cancer.

Researchers

Presenter

  • Helei Hou

Principal Investigators

  • Dong Liu

  • Na Zhou

  • Jinping Zhang

  • Chuantao Zhang

  • Mei Sun

  • Xiaoping Zhang

  • Zhe Wang

  • Xiaonan Yang

  • Zhuokun Li

  • Zhaoyang Qian

  • Renhua Wu

  • Hongmei Zhu

  • Rongjiao Wang

  • Xin Liu

  • Xiaochun Zhang

Medical Centers

  • The Affiliated Hospital of Qingdao University, Qingdao, China

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Qingdao Municipal Hospital, Qingdao University, Qingdao, China

  • Beijing Genomics Institute (BGI)-Tianjin, Tianjin, China

  • Beijing Genomics Institute (BGI)-Tianjin, Tianjin, China

  • Beijing Genomics Institute (BGI)-Tianjin, Tianjin, China

  • Weifang People's Hospital, Weifang, China

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved